37results about How to "Prevent and treat osteoporosis" patented technology

Extracts of various species of the Leguminosae family have estrogenic properties. For example, aqueous and ethanolic extracts of Pueraria lobata Willd. Ohwi of the Leguminosae family species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and / or uterine cancer, and osteoporosis.

Estrogenic compositions comprising calycosin and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

The present invention relates to furan derivatives and pharmaceutical compositions containing them to prevent and cure osteoporosis. The furan derivatives of the present invention have effect on bone proliferation with the side effect reduced, so that they can be used for bone disease.

A phamaceutical composition comprising a phenyltetrazole derivative of formula (I) or a pharmaceutical acceptable salt thereof is effective in preventing or treating osteoporosis, obesity, diabetes, or hyperlipidemia, by regulating protein TAZ.wherein, A is ethyl or n-butyl; R1 is methyl, —CH2OH, —CO2CH3, —CH2F, —CH(OCH3)2, —CH2OC(═O)CH3, styryl or —CH2OCH2SCH3; R2 is H, Br, —CO2CH3, phenyl, pyridin-2-yl, pyridin-3-yl, or styryl; R3 is H or methyl; X is CH or N; and P is H or —CH(CH3)OCH2CH3.

The present invention discloses a novel use of bakuchiol or an extract containing bakuchiol in preventing or treating a woman suffering osteoporosis. An embodiment of this novel use is a pharmaceutical composition containing bakuchiol or an extract containing bakuchiol, which can be in the dosage forms of topical use, oral administration, injection or sustained release. The present invention also discloses a novel use of bakuchiol or an extract containing bakuchiol in preventing or treating a woman suffering breast cancer.

The invention relates to novel cyclic hydrocarbon compounds and derivatives thereof, processes for the preparation thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.

Estrogenic extracts of Anemarrhena asphodeloides Bge. from the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

The present invention relates to a novel benzamidine derivative, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzamidine derivative of the present invention effectively inhibits osteoclast differentiation at an extremely low concentration, and greatly increases the trabecular bone volume, and thus it can be advantageously used for the prevention and treatment of osteoporosis.

The invention discloses a deodorized oviductus ranae egg oil composition for treating primary osteoporosis. The composition is characterized by comprising deodorized oviductus ranae egg oil, bovine bone collagen, bovine bone calcium, and achyranthes bidentata saponins. The composition is prepared into oral preparations, such as hard capsules, soft capsules, troches, granules, powder, pills, tea bags and medicinal liquors by using the synergistic effects of the ingredients. The composition can be applied to Chinese patent medicines or health foods, and has the effect of preventing osteoporosis.

The present invention relates to furan derivatives and pharmaceutical compositions containing them to prevent and cure osteoporosis. The furan derivatives of the present invention have effect on bone proliferation with the side effect reduced, so that they can be used for bone disease.

The present invention concerns a C-glucosidic ellagitannin compound or a metabolite thereof for use for altering the supramolecular arrangement of actin in an individual suffering from osteoporosis, cancer, bacterial infection, or viral infection. It also pertains to pharmaceutical compositions comprising a C-glucosidic ellagitannin compound and / or metabolites thereof and one or more physiologically acceptable carriers. It finally concerns a C-glucosidic ellagitannin compound or a metabolite thereof, optionally detectably labeled, for in vitro use as a tool for studying cellular mechanisms involving actin, or for detecting F-actin in a cell.

The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and / or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.

The present invention provides methods, compositions, and kits, for determining the effects of one or more candidate compounds on hot flash symptoms. In certain aspects, the methods, compositions, and kits can be used to identify compounds that decrease the incidence of hot flash symptoms. In other aspects, the methods, compositions, and kits can be used to determine whether candidate compounds increase the incidence of undesirable hot flash symptoms when administered to a subject.

The present invention relates to a traditional Chinese medicine composition and aims to provide the traditional Chinese medicine composition used for treating postmenopausal osteoporosis. The traditional Chinese medicine composition has functions of tonifying the kidneys and replenishing essence and strengthening bones and generating marrow, can regulate the decline of marrow-generating functionscaused by kidney qi deficiency and qi and blood deficiency in menopausal women, and prevents and treats the osteoporosis. The traditional Chinese medicine composition for treating the postmenopausal osteoporosis is composed of the following pharmaceutically effective components in parts by weight to form granules: 0.75-3 parts of prepared rehmannia root, 0.41-0.84 part of semen cuscutae, 0.75-2.25parts of radix achyranthis bidentatae, 6-9 parts of tortoise-plastron glue, 6-9 parts of deer-horn glue, 0.6-1.2 parts of Chinese yams, 0.3-1.5 parts of fructus corni, 1.81-4.55 parts of Chinese wolfberry fruits, 0.3-0.75 part of herba epimedii and 0.3-1.5 parts of glossy privet fruits.

Estrogenic extracts of Anemarrhena asphodeloides Bge. from the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

The invention relates to a composition capable of improving osteoporosis and increasing bone density. The composition comprises the following components in parts by weight of 10-30 parts of oligopeptide powder, 10-60 parts of saccharide substances, 10-60 parts of dietary fibers, 5-30 parts of maltodextrin, 5-15 parts of a calcium compound, and 0.1-2 parts of complex vitamins. When the compositionis eaten, the arthralgia can be notably reduced, the joint function can be improved, the hydroxyproline concentration in blood can be increased, the running off of sclerotin of post-menopause women suffering from osteoporosis is reduced, the treatment effect on anti-osteoporotic can be strengthened and prolonged, and the composition as a nutrient has the potential effect of preventing and treatingdegenerative arthritis and osteoporosis.

Methods and compositions for treating and preventing osteoporosis are disclosed. Osteoporosis is prevented and treated by administering an effective amount of a composition to a patient. The composition may be prepared from New Zealand green-lipped mussel (Perna canaliculus) and may comprise one or more proteins, amino acids, minerals, sterol esters, sterols, polar lipids, triglycerides, fats, lipids, fatty acids, and polyunsaturated fatty acids (PUFAs) derived from the mussel. The active ingredients in the composition include one or more of an octadecatetraenoic acid (SDA), an eicosatetraenoic acid (ETA), an eicosapentaenoic acid (EPA), and a docosahexaenoic acid (DHA).

Extracts of various species of the Polygonaceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Rheum palmatum L of the Polygonaceae family species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and / or uterine cancer, and osteoporosis.

The present invention relates to a composition for preventing or treating osteoporosis, comprising a Gentiana scabra extract and a Sambucus williamsii extract, and it is an object of the present invention to provide the composition for preventing or treating osteoporosis, which is capable of increasing bone formation and inhibiting bone resorption. In addition, it is another object of the present invention to provide the composition for preventing or treating osteoporosis, which increases bioaffinity and has no side effects by comprising a Gentiana scabra extract and a Sambucus williamsii extract, which are natural products, thereby stably exhibiting an effect of preventing or treating osteoporosis.

The invention discloses chestnut and sesame edible sauced milk. The chestnut and sesame edible sauced milk is prepared from main components and auxiliary components, wherein the main components are as follow: chestnut and sesame; and the auxiliary components are as follows: zanthoxylum schinifollum, syzygium aromaticum, honey, monosodium glutamate, table salt, soy sauce, ground pepper, cumin powder, ligusticum wallichii powder and myrcia. The chestnut and sesame edible sauced milk enriches the need of food market, remedies the blank of the sauce type milk products, is convenient to carry, is suitable for various people to eat, is available in raw material, is low in cost, and does not need fermentation treatment in the processing course, and the method is simple and feasible.